Why the study?
Does flecainide improve left ventricular dyssynchrony in infants with asymptomatic Wolff-Parkinson-White syndrome?
Does flecainide improve left ventricular dyssynchrony in infants with asymptomatic Wolff-Parkinson-White syndrome?
Flecainide may be an effective resynchronisation therapy for infants with asymptomatic Wolff-Parkinson-White syndrome and severe left ventricular dyssynchrony.
Answers are grounded in this paper and cite their sources.
Flecainide may offer resynchronization in asymptomatic WPW infants with dyssynchrony; hypothesis-generating case report requiring prospective validation.
Some asymptomatic patients with Wolff-Parkinson-White syndrome have severe left ventricular dyssynchrony and dysfunction. We describe a patient who was given a diagnosis of Wolff-Parkinson-White syndrome in infancy and had a complete response to pharmacologic therapy with flecainide. Our findings suggest that flecainide is a suitable resynchronisation therapy for such infants.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: